Small Cell Cancer Transformation of Lung Adenocarcinoma During Durvalumab Treatment After Chemoradiotherapy

J Thorac Oncol. 2020 Aug;15(8):e145-e146. doi: 10.1016/j.jtho.2019.12.117.

Authors

Sayaka Arakawa¹, Tatsuya Yoshida², Yuko Nakayama³, Noriko Motoi⁴, Yuichiro Ohe¹

Affiliations

¹ Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
² Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. Electronic address: tatyoshi@ncc.go.jp.
³ Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
⁴ Department of Pathology and Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan.

PMID: 32718542
DOI: 10.1016/j.jtho.2019.12.117

No abstract available

Publication types

Letter

MeSH terms

Adenocarcinoma of Lung / drug therapy
Antibodies, Monoclonal / therapeutic use
Chemoradiotherapy / adverse effects
Humans
Lung Neoplasms* / drug therapy

Substances

Antibodies, Monoclonal
durvalumab